SecBot SecBot
424B5 ·Filed Nov 6, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 5/10
Horizonimmediate Processed10d 10h ago SEC0001193125-26-451932
Notable filing: 424B5
Actionable Insight ▼ Bearish

The deep discount and massive dilution suggest the company needed capital urgently despite the recent FDA approval. Monitor the VOCERYQ launch trajectory and cash burn rate; the company expects funds to last only into late Q4 2027. The 90-day lock-up expiration in early February 2027 could add further selling pressure.

DirectionBearish
Confidencehigh
Horizonimmediate

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this 424B5
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.51
T+0 close · Nov 6, 2026 · via day close
Latest settled
−7.28%
T+5 · $1.40
Vs SPY
−5.59%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.51entry
  2. T+1 · 7d ago −3.97%α −3.61% · $1.45
  3. T+5 · 20h ago −7.28%α −5.59% · $1.40
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals priced a $75.0M underwritten offering of 58.7M common shares and pre-funded warrants at $1.05 per share, a 27.6% discount to the $1.45 last reported sale price. The offering follows the October 30 FDA accelerated approval of VOCERYQ and the company's disclosure of only $48.4M in cash, with a going concern warning. Proceeds will fund the VOCERYQ commercial launch and pipeline development, but the massive dilution (53% of pre-offering shares outstanding) and deep discount signal acute capital needs at a $168M market cap.

Key Financial Metrics

Offering Size
$75.0M
Dilution
53.3%
Lock-up
90 days
Underwriters
Jefferies LLC, Piper Sandler & Co. +1

Key Facts

  • 58,747,235 common shares and pre-funded warrants for 12,681,337 shares offered at $1.05 per share
  • Offering price is a 27.6% discount to the $1.45 last reported sale price on November 5, 2026
  • Total gross proceeds of approximately $75.0M; net proceeds estimated at $70.0M
  • Shares outstanding will increase from 110.2M to 168.9M (53% dilution) excluding pre-funded warrants
  • Underwriters have a 30-day option for an additional 10,714,285 shares
  • Company had only $48.4M in cash as of September 30, 2026 and disclosed substantial doubt about going concern
  • FDA granted accelerated approval of VOCERYQ on October 30, 2026, just 6 days before this offering
  • 90-day lock-up agreements for company, officers, and directors
  • Underwriters: Jefferies, Piper Sandler, H.C. Wainwright

Financial Impact

$75.0M gross proceeds raised at a 27.6% discount to market, representing 53% dilution to existing shareholders

dilutioncashmarket capitalization

Risk Factors

  • 53% dilution from this offering alone, with additional dilution from pre-funded warrants and outstanding options/warrants
  • Going concern warning and only $48.4M cash pre-offering despite recent FDA approval
  • VOCERYQ commercial launch may not generate sufficient revenue to offset ongoing losses
  • Continued approval of VOCERYQ contingent on confirmatory trial results
  • 13 equity offerings in the last 24 months signal persistent capital needs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-451932
Document: 0001193125-26-451932-index-headers.html0001193125-26-451932
Document: 0001193125-26-451932-index.html0001193125-26-451932
Document: 0001193125-26-451932.txt0001193125-26-451932

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Viewing Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026